Introduction
============

Esophageal cancer is a common type of malignant tumor of the digestive tract that originates from the esophageal epithelium or glands ([@b1-ol-0-0-9904]). Based on the International Agency for Research on Cancer statistics, 455,800 new esophageal cancer cases were estimated and 400,200 mortalities occurred in 2012 worldwide, which makes the incidence and mortality rates of esophageal cancer the eighth and sixth highest in the world, respectively ([@b2-ol-0-0-9904]). Esophageal cancer can predominantly be divided into esophageal squamous cell carcinoma (ESCC) and adenocarcinoma, and \>90% of esophageal cancer cases are classified as ESCC in China ([@b3-ol-0-0-9904]). Despite improvements in diagnosis and treatment, the survival rate of patients with advanced stages of ESCC remains poor. In 2014, based on a long-term follow-up survey of 21 cancer registries, the National Cancer Center estimated that the 5-year survival rate of esophageal cancer in China was 20.9% ([@b4-ol-0-0-9904]). The Xinjing Kazakh ethnic group is a Chinese minority with a high incidence of esophageal carcinoma ([@b5-ol-0-0-9904]). Studies suggest that the mortality rate of esophageal cancer for people of Kazakh ethnicity in the Xinyuan County of Xinjiang was 0.0411% between 2000 to 2005, which was much higher compared with that for individuals of the local Han ethnicity (0.0088%) ([@b6-ol-0-0-9904]), which suggests ESCC poses a serious threat to the health condition of Kazakh individuals. Therefore, novel biomarkers that can assist with the early detection of ESCC in Kazakh patients are urgently required.

microRNAs (miRNAs) are a class of non-coding RNAs comprising of 19--24 nucleotides that regulate gene expression through post-transcriptional, RNA interference and gene silencing pathways ([@b7-ol-0-0-9904]). miRNAs can inhibit gene expression through complementary binding to the 3′-untranslated region of the target mRNAs ([@b8-ol-0-0-9904]). miRNAs have been demonstrated to be crucial for cancer initiation, progression and dissemination ([@b9-ol-0-0-9904]). It has been identified that \>50% of miRNAs are encoded in chromosome fragile sites, which are frequently absent, amplified or rearranged in malignant tumor cells, thereby resulting in the dysregulated expression of miRNAs ([@b10-ol-0-0-9904]). An estimated 30% of human protein-coding genes are regulated by miRNAs ([@b11-ol-0-0-9904]). Furthermore, miRNAs serve key roles in tumor progression and resistance to chemotherapy by regulating the expression of oncogenes and tumor suppressor genes ([@b12-ol-0-0-9904]). Previous studies have indicated that various miRNAs are associated with ESCC in Kazakh patients ([@b13-ol-0-0-9904],[@b14-ol-0-0-9904]). However, to the best of our knowledge, no previous studies have performed an analysis on the whole genome level. In recent years, the combination of high-throughput sequencing and bioinformatics analysis has made it possible to analyze the role of miRNAs that are differently expressed in ESCC in Kazakh patients. In the present study, to identify miRNA signatures in ESCC in Kazakh patients and uncover their potential mechanisms, microarray analysis was used to identify differently-expressed miRNAs between three paired ESCC and normal esophageal tissue samples from Kazakh patients. Furthermore, bioinformatic methods were used to analyze the functions of the differentially-expressed miRNAs.

Patients and methods
====================

### Clinical characteristics and tissue samples

A total of 13 samples of ESCC tissue and corresponding adjacent normal tissue were obtained from patients with esophageal squamous cell carcinoma treated surgically at the First Affiliated Hospital of Medical College of Shihezi University (Shihezi, China) from November 2014 to September 2015. Among them, three samples were used for microarray testing, including two samples obtained from males and one from a female (age range, 63--70 years). In addition, ten samples were used for reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis, including five from males and five from females (age range, 62--75 years). No patients had a history of smoking and drinking, and no chemoradiotherapy was received prior to surgery. All tumors were stage T2N1M0 ([@b15-ol-0-0-9904]). All tumor samples were confirmed by two pathologists as moderately differentiated ESCC. The collection of specimens was approved by the Ethics Committee of the First Affiliated Hospital of Medical College of Shihezi University and authorized by the patients or family members. Each tissue sample was transferred to liquid nitrogen immediately following surgery and stored in a −80°C freezer. All microarray experiments were completed at CapitalBio Corporation (Beijing, China).

### RNA extraction and whole genome miRNA profiling

Total RNA was isolated from \~2--3 g (2×2×2 cm^3^) of tumor tissue samples and the corresponding normal tissue samples. Total RNA from frozen tumor tissue samples was extracted using an Ambion mirVana miRNA Isolation kit (Ambion; Thermo Fisher Scientific, Inc., Waltham, MA, USA), according to the manufacturer\'s protocol. The quality and quantity of total RNA samples were tested using a spectrophotometer. A preparation of RNA with an A260/A280 ratio of 1.8--2.0 was used for the microarray analysis. Formaldehyde denaturing gel electrophoresis was also used to test the quality of total RNA. When the 28S:18S ribosomal RNA ≥1:1, it met the experimental requirements for gene chip array analysis. Affymetrix GeneChip miRNA 4.0 Arrays (Affymetrix; Thermo Fisher Scientific, Inc.) were used to detect the miRNAs in the samples. All miRNAs were labeled with biotin using a FlashTap RNA Labeling kit (Genisphere LLC, Hatfield, PA, USA), and subsequently chip hybridization and data analysis were performed. According to Significance Analysis of Microarrays software R2.0 ([@b16-ol-0-0-9904]), q\<0.05 and fold change ≥2 or ≤0.5 indicated a statistically significant differentially expressed miRNA.

### Prediction of miRNA targets and functional enrichment analysis

The target genes of the identified miRNAs were predicted using miRWalk (<http://mirwalk.uni-hd.de/>), which includes 12 databases, including TargetScan, miRanda and MiRmap. Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were applied using KOBAS 2.0 (<http://kobas.cbi.pku.edu.cn.>). Fisher\'s exact test was performed to classify the GO terms and KEGG pathways, and P\<0.05 indicated a statistically significant GO term or KEGG pathway.

### Generation of a protein-protein interaction (PPI) network

Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database (<https://string-db.org/cgi/input.pl>) is an online tool for analyzing protein-protein interaction information. To analyze the interactions of the target genes, the genes were mapped to the STRING database and a PPI network was constructed. Cytoscape 3.6.0 ([@b17-ol-0-0-9904]) was used to visualize the PPI network and identify the hub genes. The node degrees of the target genes were analyzed and the first five were selected as the network\'s hub genes.

### Integration of miRNA-mRNA co-expression network

The correlation test within the 'stats' package in R 2.15.3 (<http://www.R-project.org/>) was used for the co-expression analysis. According to the principle of negative interaction between miRNA and mRNA, a miRNA-mRNA co-expression network was integrated using P\<0.05 and correlation coefficient \<-0.99, Pearson\'s correlation coefficient was used for the correlation analysis. Cytoscape software was then used to generate a co-expression network.

### RT-qPCR

An additional 10 Kazakh ESCC tissue samples and corresponding adjacent normal tissue samples were obtained for RT-qPCR verification. Total RNA extraction was performed using the aforementioned method. Subsequently, a miRcute miRNA First-Strand cDNA Synthesis kit and a miRcute miRNA qPCR Detection kit (SYBR^®^ Green; both from Tiangen Biotech Co., Ltd., Beijing, China) were used to detect the levels of miRNA, according to the manufacturer\'s protocols. U6 was used as an internal control. The RT reaction system (20 µl) contained 2 µl total RNA, 10 µl 2X miRNA RT reaction buffer, 2 µl miRNA RT enzyme mix and 6 µl RNase-free ddH2O. The reactions were performed at 42°C for 60 min and 95°C for 3 min. The 20 µl reaction system for qPCR included 10 µl 2X miRcute Plus miRNA Premix (with SYBR and ROX), 1 µl forward primer, 0.4 µl reverse primer (10 µM), 2 µl first-strand cDNA and 6.6 µl ddH~2~O. Amplification was performed under the following reaction conditions: 95°C for 15 min, followed by 40 cycles of 94°C for 20 sec and 60°C for 34 sec. qPCR was performed on a CFX96 Real-Time system (Bio-Rad Laboratories, Inc., Hercules, CA, USA) using the following forward primers: U6, 5′-GCTTCGGCAGCACATATACTAAAAT-3′; miR-664b-5p, 5′-TGGGCTAAGGGAGATGATTGGGTA-3′; miR-767-5p, 5′-TGCACCATGGTTGTCTGAGCATG-3′; miR-223-3p, 5′-GCGTGTCAGTTTGTCAAATACCCCA-3′; miR-203a, 5′-cgcAGTGGTTCTTAACAGTTCAACAGTT-3′; miR-373, 5′-GACGAGCCCCTCGCACAAAC-3′. The reverse primers were contained in the miRcute miRNA qPCR Detection kit. Relative quantification of miRNA expression was calculated using the 2^−∆∆Ct^ method ([@b18-ol-0-0-9904]) the data were statistically analyzed by Student\'s t-tests, and P\<0.05 was considered to indicate a statistically significant differences between groups. For each sample, all experiments were performed in triplicate.

Results
=======

### Identification of differentially-expressed miRNAs

To determine the miRNA expression patterns in ESCC tissue samples and their corresponding normal tissue samples, miRNA microarray analysis was conducted. A total of 23 miRNAs were identified to be significantly differentially expressed between the two groups; 12 miRNAs were upregulated and 11 miRNAs were downregulated. As demonstrated in [Figs. 1](#f1-ol-0-0-9904){ref-type="fig"} and [2](#f2-ol-0-0-9904){ref-type="fig"}, the expression of these miRNAs differed between Kazakh ESCC and matched normal tissues. The differentially expressed-miRNAs are displayed in [Table I](#tI-ol-0-0-9904){ref-type="table"}.

### Target gene prediction

miRWalk 2.0 was used to predict the target genes of the differentially-expressed miRNAs. Of the 23 differentially-expressed miRNAs, 224 target genes were predicted for 21 miRNAs, as presented in [Table II](#tII-ol-0-0-9904){ref-type="table"}.

### KEGG pathway analysis

Using KEGG pathway analysis, a total of five terms were enriched among the upregulated miRNAs and eight terms were enriched among the downregulated miRNAs. [Table III](#tIII-ol-0-0-9904){ref-type="table"} presents the significantly enriched pathways of the differently-expressed miRNAs. The upregulated miRNAs were identified to be predominantly involved in the following pathways: 'Glycosphingolipid biosynthesis-ganglio series' and 'Endocrine and other factor-regulated calcium reabsorption'. The downregulated miRNAs were revealed to be involved in the following pathways: 'Endocrine and other factor-regulated calcium reabsorption', 'Lysine degradation' and 'Steroid biosynthesis'.

### GO term enrichment analysis

To further understand the associated functions of the differently-expressed miRNAs, GO analysis was performed. GO enrichment analysis included the categories cellular component, biological process and molecular function. A total of 750 terms were enriched for the upregulated miRNAs ([Fig. 3](#f3-ol-0-0-9904){ref-type="fig"}) and 888 terms were enriched for the downregulated miRNAs ([Fig. 4](#f4-ol-0-0-9904){ref-type="fig"}).

### Protein-protein interaction (PPI) network analysis

Based on the information in the STRING database, a PPI network ([Fig. 5](#f5-ol-0-0-9904){ref-type="fig"}) of the target genes was generated. Cytoscape software analysis of the target genes in the network revealed a maximum node degree of seven and a minimum of one. The following top five hub genes were selected: IQ motif containing GTPase activating protein 1 (IQGAP1), RAB11A, lysine acetyltransferase 2B (KAT2B), catenin α 1 (CTNNA1) and tight junction protein 2 (TJP2).

### Integration of miRNA-mRNA co-expression network

According to the principle of negative interaction between miRNA and mRNA, miRNAs and mRNAs with a correlation coefficient \<-0.99 were selected to establish the miRNA-mRNA co-expression network using Cytoscape software. The network comprised of 273 nodes and 326 edges. As depicted in [Fig. 6](#f6-ol-0-0-9904){ref-type="fig"}, the network consisted of 21 miRNAs (11 upregulated and 10 downregulated) and 252 mRNAs. The co-expression network demonstrates that the mRNAs may be potential target genes of the differently-expressed miRNAs and the mRNAs may be involved in the occurrence and development of ESCC.

### Identification of final target genes of differentially expressed miRNAs

If the target mRNAs predicted by miRWalk also appeared in the co-expression network they were designated as the final target genes. A total of 25 mRNAs and 11 miRNAs were presented in the co-expression network ([Fig. 7](#f7-ol-0-0-9904){ref-type="fig"}).

### Validation of microarray data using RT-qPCR

To validate the microarray data, RT-qPCR was performed to detect the expression level of certain selected differentially-expressed miRNAs, including miR-664b-5p, miR-767-5p, miR-223-3p, miR-203a and miR-375. The RT-qPCR results and microarray data were consistent ([Fig. 8](#f8-ol-0-0-9904){ref-type="fig"}).

Discussion
==========

The incidence of esophageal cancer is not only associated with environmental factors, living habits, microorganisms and other external factors, but also closely associated with genetic factors and differential gene expression ([@b19-ol-0-0-9904]). Therefore, it is important to investigate the differentially-expressed genes involved in the pathogenesis of esophageal carcinoma. Microarray and high-throughput sequencing technology are beneficial methods for detecting the expression of thousands of genes simultaneously; therefore, these methods are frequently used to investigate potential biological targets for the diagnosis and treatment of esophageal cancer ([@b20-ol-0-0-9904],[@b21-ol-0-0-9904]). Although numerous studies have been devoted to the differential expression of genes associated with esophageal cancer in Kazakh patients ([@b22-ol-0-0-9904],[@b23-ol-0-0-9904]), to the best of our knowledge, the expression of miRNAs has not been systematically evaluated. In the present study, the differentially-expressed miRNAs in Xinjiang Kazakh cases of ESCC were identified by microarray analysis and their biological functions were preliminarily analyzed. This may enrich the investigation of the gene expression profiles in Kazakh ESCC.

The present study identified 23 differentially-expressed miRNAs between ESCC and normal control tissues. Among these miRNAs, certain miRNAs have previously been identified to be differentially expressed in esophageal cancer. Li *et al* ([@b24-ol-0-0-9904]) revealed that miR-375 was frequently downregulated in ESCC and was significantly associated with advanced clinical stage, tumor metastasis and poor prognosis, which indicates that miR-375 may serve as a potential biomarker to predict the outcome of ESCC. In ESCC tissue obtained from Kazakh patients, the expression of miR-375 was also identified to be downregulated in another study ([@b25-ol-0-0-9904]), which is consistent with the present findings. Therefore, it could be indicated that miR-375 acts as a tumor suppressor in ESCC. Wang *et al* ([@b26-ol-0-0-9904]) reported that miR-3651 was downregulated in ESCC of Han patients, and was negatively correlated with T stage and tumor size. However, in the present study it was identified that miR-3651 was upregulated. This difference may be explained by differences between the sample populations. Han and Kazakh patients may have different miRNA expression profiles, and miR-3651 may serve a different role in ESCC in patients of the two ethnicities. miR-203 has been demonstrated to be downregulated in a number of malignant tumor types, including laryngeal squamous cell carcinoma ([@b27-ol-0-0-9904]), hepatocellular carcinoma ([@b28-ol-0-0-9904]), cervical cancer ([@b29-ol-0-0-9904]) and lung cancer ([@b30-ol-0-0-9904]). Similar to the current study, Li *et al* ([@b31-ol-0-0-9904]) demonstrated that miR-203a is downregulated in ESCC samples and the transfection of miR-203a in cells mimicking esophageal cancer inhibited their proliferation and invasive capacity, indicating that miR-203a serves a tumor suppressor role. Several studies have identified that miR-21-3p is upregulated in ESCC tissue samples, which indicates miR-21-3p may serve as an oncogene by participating in the invasion and metastasis of esophageal cancer ([@b32-ol-0-0-9904]). Similar to the present study, Liu *et al* ([@b33-ol-0-0-9904]). reported that miR-21 is highly expressed in esophageal cancer in patients of Kazakh ethnicity, and serves a negative role in regulating programmed cell death. miR-25, a member of the miR-106b-25 cluster ([@b34-ol-0-0-9904]), has been identified to be overexpressed in several cancer types, including small cell lung, gastric and liver cancer ([@b31-ol-0-0-9904],[@b35-ol-0-0-9904]--[@b37-ol-0-0-9904]). Xu *et al* ([@b38-ol-0-0-9904]) demonstrated that high expression of miR-25 is associated with lymph node metastasis and Tumor-Node-Metastasis stage in patients with ESCC. This study suggests that miRNA-25 is upregulated in Kazakh ESCC and may serve a role as an oncogene.

Furthermore, certain differentially-expressed miRNAs identified in the present study have previously been reported in other various cancer types, including breast cancer, glioma, lung cancer and hepatocellular carcinoma ([@b39-ol-0-0-9904]--[@b43-ol-0-0-9904]), but have not been previously identified in Kazakh ESCC. These miRNAs may serve important roles in the development and progression of ESCC. Additionally, to the best of our knowledge, certain miRNAs revealed in the present study have not previously been reported in any tumor types, therefore these may be potential novel markers of Kazakh ESCC. Further experiments are required to verify this observation. Additionally, RT-qPCR was used to detect the expression levels of certain miRNAs, including miR-664b-5p, miR-767-5p, miR-223-3p, miR-203a and miR-375, which were identified to be differentially expressed using microarray analysis. These results confirmed that RT-qPCR and gene chip detection were in accordance, which supports the accuracy of the microarray results.

The number and type of differentially expressed miRNAs in the current study varies from previous studies ([@b20-ol-0-0-9904],[@b44-ol-0-0-9904]). A number of factors can affect the results of microarray analysis, including the homogeneity of the sample and differences in the chips used. The current study maximized homogeneity in the selection of samples. All patients were diagnosed with primary ESCC. No patients had a history of smoking and drinking, and no chemoradiotherapy was received prior to surgery. All cancer specimens were confirmed as moderately differentiated ESCC and the tumor staging was T2N1M0. It can be hypothesized that differences with previous studies may be associated with differences in the number of samples, the region the samples were acquired from, experimental conditions, research methods, the specific chips used and the data analysis methods. Furthermore, due to different genetic backgrounds, the gene expression profile of ESCC may be different in Kazakh patients compared with Han patients. Therefore, studying the specific markers of Kazakh ESCC is important for understanding its pathogenesis.

KEGG analysis demonstrated that the differentially expressed miRNAs were mainly involved in 'glycolipid biosynthesis', 'endocrine and other glycolipid-related factors regulating calcium reabsorption' and 'steroid biosynthesis'. According to a previous study, abnormal expression of glycolipids in tissues and organs may lead to carcinogenesis ([@b45-ol-0-0-9904]), and the abnormal metabolism of steroids is closely associated with the occurrence, metastasis and treatment of tumors ([@b46-ol-0-0-9904]). Calcium ion is an important second messenger within the cell. It can participate in the proliferation, differentiation, metastasis and apoptosis of tumors in numerous ways. Therefore, the abnormal absorption of calcium ions in cells may be closely associated with tumorigenesis ([@b47-ol-0-0-9904]). GO analysis indicated that the upregulated miRNAs were mainly associated with vesicles and exocrine bodies. By contrast, the downregulated miRNAs were mainly associated with the negative regulation of integrin-mediated signaling pathways, lipid binding and other functions. The exosecretion ([@b48-ol-0-0-9904]) and integrin-mediated signaling pathways ([@b49-ol-0-0-9904]) have previously been confirmed to be associated with tumors. The upregulation or downregulation of these functions may directly or indirectly lead to the occurrence and development of tumors, which suggests the differentially expressed miRNAs associated with these biological processes may be associated with ESCC. However, the specific mechanisms remain to be further elucidated.

As demonstrated in the PPI network, IQGAP1, RAB11A, KAT2B, CTNNA1 and TJP2 were identified as hub genes. IQGAP1 is a scaffolding protein that can regulate several distinct signaling pathways ([@b50-ol-0-0-9904]). Accumulating evidence has demonstrated that IQGAP1 serves an important role in tumorigenesis and tumor progression. Andl *et al* ([@b51-ol-0-0-9904]) demonstrated that IQGAP1 was overexpressed in ESCC tumor tissues and its overexpression was correlated with the invasion depth of ESCC. Therefore, IQGAP1 may be important in regulating ESCC occurrence and progression and may be useful in developing a novel anticancer therapy. Xu *et al* ([@b52-ol-0-0-9904]) identified that RAB11A was upregulated in ESCC and may serve a critical role in the development of ESCC. Other studies have demonstrated that KAT2B, CTNNA1 and TJP2 are important in multiple tumor types, including hepatocellular carcinoma, cervical cancer and breast cancer ([@b53-ol-0-0-9904]--[@b55-ol-0-0-9904]), however their roles in ESCC are not clear. In the current study, these three genes were targeted by the differentially expressed miRNAs in Kazakh ESCC, which suggests that they may also serve an important role in the development of ESCC.

The occurrence and development of esophageal cancer is associated with a number of factors. The most common risk factors of esophageal cancer include smoking, drinking and human papillomavirus infection. miRNAs are also widely involved in the progression of tumor formation ([@b19-ol-0-0-9904]). The effect of different risk factors and clinicopathological features on the expression of miRNA in esophageal cancer can be analyzed by gene chip technology, a method used to understand molecular mechanisms and provide diagnostic markers or new targets for therapy ([@b44-ol-0-0-9904]). Unfortunately, due to the limitation of the sample size in the current study, the correlations were not explored between the differential expression of miRNAs, clinicopathological characteristics and risk factors. Future studies should investigate these correlations by expanding the sample size.

The current study predicted the target genes of the differentially expressed miRNAs and then used bioinformatics to analyze the functions of these genes. The differentially expressed miRNAs may serve important roles by regulating these functions. Although the mechanisms of how the differentially expressed miRNAs contribute to the development of Kazakh ESCC are unknown, the findings of the current study provides the prerequisite for a future study to identify useful markers for diagnosing and treating Kazakh ESCC. Subsequent experiments are required to further clarify the roles and mechanisms of the differentially expressed miRNAs and their target genes in ESCC both *in vivo* and *in vitro*.

In conclusion, the current study performed a preliminary analysis of the biological effects of differentially expressed miRNAs in ESCC in Kazakh patients, which may be associated with the occurrence of the disease. Several potential target genes of these miRNAs were also identified. Studying these target genes can increase our understanding of the underlying mechanisms, which in turn can assist the discovery of improved uses of these differential miRNAs, possibly as markers of clinical diagnosis or therapeutic targets. The current findings can apply not only to all patients with ESCC, but also Kazakh patients with unique clinicopathological features. Further studies are needed to verify the role of these differentially expressed miRNAs in Kazakh ESCC.
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###### 

Expression of microRNAs in Kazakh esophagus squamous cell carcinoma tissues and corresponding normal tissues.

  Gene name          Fold change   q-value   Regulation
  ------------------ ------------- --------- ------------
  hsa-miR-664b-5p    26.4885       0.0316    Up
  hsa-miR-767-5p     25.0685       0.0316    Up
  hsa-miR-1301-3p    8.5011        0         Up
  hsa-miR-93-3p      8.3847        0         Up
  hsa-miR-21-3p      7.9849        0         Up
  hsa-miR-25-5p      6.9362        0.0195    Up
  hsa-miR-3651       5.9744        0         Up
  hsa-miR-99b-5p     5.0415        0.0316    Up
  hsa-miR-223-3p     4.3435        0         Up
  hsa-miR-505-5p     3.5862        0         Up
  hsa-miR-1273h-5p   3.0283        0         Up
  hsa-miR-423-5p     2.4030        0.0195    Up
  hsa-miR-6086       0.4195        0.0397    Down
  hsa-miR-3663-3p    0.3356        0.0373    Down
  hsa-miR-378e       0.3160        0.0373    Down
  hsa-miR-5100       0.2901        0.0498    Down
  hsa-miR-1273g-3p   0.2163        0         Down
  hsa-miR-422a       0.1372        0.0397    Down
  hsa-miR-1224-5p    0.1277        0.0373    Down
  hsa-miR-203a       0.1094        0.0397    Down
  hsa-miR-617        0.0818        0         Down
  hsa-miR-375        0.0666        0.0373    Down
  hsa-miR-5580-3p    0.0186        0         Down

###### 

Target genes of differentially expressed miRNAs.

  miRNA              Target gene                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Expression
  ------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------
  hsa-miR-99b-5p     N4BP3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Up
  hsa-miR-93-3p      ABLIM1, AMFR, C6orf132, CCNG2, COL4A3BP, CYP11A1, FAM46B, FYCO1, GANC, GIPC1, H2AFY, IKZF2, KLF8, KLHL2, LCOR, LYNX1, MUC1, N4BP3, NFIA, PRNP, RMND5B, SIM2, SLC12A7, SORT1, TMEM201, TPCN1, TRPS1                                                                                                                                                                                                                                                                                                                                                                     Up
  hsa-miR-767-5p     ABLIM1, ARSB, ATP1B1, CCNG2, CD276, CDH3, CHIC2, CUL3, CYP24A1, ELOVL6, ERAP1, FAM126B, FNDC3B, FUT2, GABRP, GANC, GLI2, IQGAP1, LAMC2, LCOR, NDST1, NFIA, PHACTR4, PI15, PIK3C2A, PPL, PRDM1, RAB11A, SCNN1B, SDK1, SEC24A, SERAC1, SFXN3, SH3TC2, TET2, TGIF2, TJP2, TMEM79, TRPS1, ZBTB43                                                                                                                                                                                                                                                                           Up
  hsa-miR-664b-5p    NFIA, LCOR, TGIF2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Up
  hsa-miR-505-5p     AGFG2, AIF1L, CAPN5, CCDC120, CD276, CDK18, EPN3, FAM189A2, FMO2, GABRP, GANC, GDI1, IL1RN, KCNQ2, KIAA0232, KIF1C, KREMEN1, TET2, MARK2, N4BP3, NDST1, NT5C2, OCLN, PITPNM3, PRNP, RARG, RMND5B, SCP2, SDK1, SLC25A23, SLC2A3, SMAGP, SORT1,TGIF2, TMPRSS2, UNC13B                                                                                                                                                                                                                                                                                                    Up
  hsa-miR-423-5p     ARSB, ABR, ADCY6, AGFG2, ANXA9, ARHGAP32, ARHGEF10L, B4GALNT1, BAG1, CACNG4, CAPN5, CD276, CSF1, CUL3, CYP4F22,DIAPH1, ELF3, ELOVL6, EMP1, ESRP2, FAM129B, FBXO34, FOSL2, FYCO1,GANC, GATSL3, GDI1, GPX3, HEXIM1, HLF, KREMEN1, LCOR, LYNX1,MAP3K9, MARK2, MGLL, MKNK2, N4BP3, NAT14, NCCRP1, NDST1, NPR3,PAQR8, PDLIM5, PI15, PIM1, PMM1, PRDM1, PTK6, RAB25, RABGAP1L,RALB, RFFL, SAR1B, SDK1, SH3TC2, SLC25A23, SLC2A3, SLC35C1, SORT1,ST6GALNAC6, THRB, TMEM144, TMEM201, TOM1, TPCN1, TRPS1, TYRO3, VAT1, VAV3                                                    Up
  hsa-miR-3651       COBLL1, FBXO34, IKZF2, MGLL, NFIA, SLC17A5, ST3GAL4, TRIM13, VAV3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Up
  hsa-miR-25-5p      ABR, BNIPL, EXPH5, FAM114A1, FUT2, MARK2, KIF1C, OCLN, PHACTR4, TGIF2, TRIM9, ZNF185                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Up
  hsa-miR-223-3p     ABLIM1, ACPP, AIM1, ATP1B1, C1orf116, CAMSAP1, CAPN14, CDKN2AIP, CDOCK9, FAM219B, HEXIM1, HLF, LAMC2, LCOR, LIN54, LNPEP, TAOK3, RALGPS2, MSMO1, NCCRP1, NFIA, PIK3C2A, PLD1, PRDM1, RAB11FIP1, ABGAP1L, RASEF, SFXN3, SH3TC2, SIM2, SLC26A2, TRPS1, TWF1, DS1                                                                                                                                                                                                                                                                                                         Up
  hsa-miR-21-3p      AMFR, ATP1B1, CAMSAP1, CAPN5, CD46, CDK18, COBLL1, CUL3, WDR47, FAM135A, FAM219B, FNDC3B, FYCO1, HLF, LCOR, LIN54, LYNX1, STAU2, MGLL, MLLT4, NPR3, OCLN, PCYOX1, PI15, PLOD1, PMM1, PRDM1, TET2, PRKCH, RBM47, ROBO2, SAR1B, SLC26A2, ST6GALNAC6                                                                                                                                                                                                                                                                                                                      Up
  hsa-miR-1301-3p    AGFG2, ARHGAP32, BACH1, CAMSAP1, CAPN14, CCNG2, CD276, MOXD1, CLCN3, CXCL1, DIAPH1, ELF3, EPN3, FAM114A1, FAM219B, CD46, FYCO1, GANC, GRHL1, IKZF2, KLHL2, KREMEN1, LAMB3, LCOR, PRDM1, SORT1, FUT2, LIN54, LYNX1, MMP11, FBXO34, TET2, NAPA, NDST1, NFIA, TRPS1, NT5C2, PAQR8, PCSK5, PITX1, PRNP, RBM47, ROBO2, SAR1B, VAV3, TOM1, SASH1, SH3TC2, SIM2, SLC25A23, SLC26A2, ZBTB43, TMEM108, TOM1L2, TMEM201, TRIM9, NPR3,                                                                                                                                            Up
  hsa-miR-1273g-3p   ABLIM1, ARSB, CAMSAP1, CCNG2, CLCN3, GNE, GOLGA2, LIN54, NFIA, PCYOX1, PRDM1, RABGAP1L, RFFL, SDK1, SH3TC2                                                                                                                                                                                                                                                                                                                                                                                                                                                             Down
  hsa-miR-1224-5p    ABLIM1, AIF1L, ALDH9A1, B4GALNT1, CAPN5, CD207, ZBTB43, SLC2A3, CYP4F22, FAM129B, FBXO34, FMO2, FNDC3B, FYCO1, HEXIM1, USP54, KAT2B, KIAA0232, PITPNM3, LCOR, MARVELD3, MOXD1, NAT14, NDRG2,PAQR8, PCYOX1, PHACTR4, TMEM108, PITX1, RAI1, RBM47, SCP2, SDK1,SLC35C1, SNX33, TMPRSS11B, TRIM13, TRPS1, UPRT, EPN3, THRB, CUL3, DLX1, BAG1                                                                                                                                                                                                                               Down
  hsa-miR-617        ABHD17B, AMFR, ARHGAP32, CAPN5, CCDC150, CDS1, CUL3, ERAP1, FAM219B, FNDC3B, GABRP, GRHL1, HES5, HLF, HOOK3, KANK1, LYNX1, NDST1, NFIA, OCLN, PCYOX1, PRKCH, RAB11FIP1, RALGPS2, SEC24A, SH3TC2, SLC26A2, SORT1, TET2, TGIF2, TMEM201                                                                                                                                                                                                                                                                                                                                  Down
  hsa-miR-6086       MARK2, GIPC1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Down
  hsa-miR-5580-3p    ARHGAP32, ATP1B1, ERAP1, ESRP1, FAM126B, FMO2, FNDC3B, SPTLC1, KLF8, MLLT4, GNE, PCYOX1, PI15, PIK3C2A, PRDM1, PRKCH, TMEM108, SAR1B, SH3TC2, SLC2A3, NFIA, OCLN, RASEF                                                                                                                                                                                                                                                                                                                                                                                                Down
  hsa-miR-5100       ANXA9, ARHGAP32, BARX2, EXPH5, FAM114A1, KANK1, KLB, NPR3, RAB11A, RALB, PRKCH, PHACTR4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Down
  hsa-miR-422a       ABR, ALDH3A2, AMFR, CCNG2, COL4A3BP, CTNNA1, CUL3, DLX1, ESRP2, VAT1, C1orf116, GOLPH3L, HOOK3, IKZF2, KLF8, LIN54, MOXD1, SH3TC2, NDST1, NR1H2, PAQR8, PCYOX1, PEBP1, PI15, PIM1, PIM2, PLOD1, PRKCH, RAB11A, SLC2A3, SLC35C1, TWF1, TRAF6, FYCO1                                                                                                                                                                                                                                                                                                                     Down
  hsa-miR-378e       CCNG2, GOLPH3L, PEBP1, PRKCH, RAB11A, SH3TC2, SLC2A3, TWF1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Down
  hsa-miR-375        ABLIM1, ADCY6, AIM1, ATP1B1, BAG1, CACNG4, CAST, CLCN3, SERAC1, COBLL1, CXCL1, CXCR2, ELOVL6, FAM135A, FMO2, FNDC3B, RMND5B, IKZF2, KLF8, N4BP3, NFIA, NPR3, NT5C2, OCLN, PCYOX1, PRDM1, SAMD9, RAB11A, RALGPS2, RBM47, PLD1, SLC25A23, CDS1, GANC, ROBO2, THRB, TMEM144, TRPS1, UNC13B, TGIF2, SEC24A                                                                                                                                                                                                                                                                 Down
  hsa-miR-203a       ABLIM1, ACPP, AIF1L, AIM1, ALDH3A2, ANKRD44, ARHGAP32, ARSB, BAG1, CCNG2, CAPN14, CD46, CITED2, CLCN3, COBLL1, CUL3, CYP24A1, DUSP5, ELOVL6, HEXIM1, EMP1, GNE, EPN3, ERAP1, FAM114A1, FYCO1, FAM126B, FMO2, FNDC3B, FOSL2, GOLPH3L, GRHL3, HLF, HOOK3, IKZF2, LCOR, LIN54, MLLT4, MSMO1, GLTP, N4BP3, NPR3, OVOL1, PAQR8, PHACTR4, PI15, PIK3C2A, PITPNM3, PLD1, RAB11A, SEC24A, SDK1, VAV3, RABGAP1L, RALB, RBM47, ROBO2, SAR1B, SASH1, SCEL, SCP2, ZNF571, ZNF185, SH3TC2, SLC25A23, SLC26A2, SLC2A3, TET2, THRB, TMEM154, TRPS1, TWF1, VAT1, NFIA, ZNF442, WDR47   Down

miRNA, microRNA.

###### 

Top Kyoto Encyclopedia of Genes and Genomes enrichment terms for the differentially expressed microRNAs.

  Term                                                        ID         P-value   Regulation
  ----------------------------------------------------------- ---------- --------- ------------
  Glycosphingolipid biosynthesis-ganglio series               hsa00604   0.012     Up
  Endocrine and other factor-regulated calcium reabsorption   hsa04961   0.014     Up
  Steroid biosynthesis                                        hsa00100   0.020     Up
  Glycosphingolipid biosynthesis-lacto and neolacto series    hsa00601   0.032     Up
  Thyroid hormone synthesis                                   hsa04918   0.040     Up
  Endocrine and other factor-regulated calcium reabsorption   hsa04961   0.015     Down
  Lysine degradation                                          hsa00310   0.018     Down
  Steroid biosynthesis                                        hsa00100   0.020     Down
  Endocytosis                                                 hsa04144   0.025     Down
  Histidine metabolism                                        hsa00340   0.026     Down
